ArticleFrontiers in immunology2018
LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- Biochemical bone biomarkers in plasma cell dyscrasias.British journal of haematology · 2026Review
- High levels of LIGHT/TNFSF14 in patients with Prader-Willi syndrome.Journal of endocrinological investigation · 2023Article
- Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents.Journal of bone and mineral metabolism · 2023Review
- Mechanical stimuli-mediated modulation of bone cell function-implications for bone remodeling and angiogenesis.Cell and tissue research · 2021Review
- Molecular and Clinical Characterization of LIGHT/TNFSF14 Expression at Transcriptional LevelFrontiers in molecular biosciences · 2021Article
- Editorial: Special Issue on "Molecular Mechanisms Regulating Osteoclastogenesis".International journal of molecular sciences · 2020Article
- Shedding "LIGHT" on the Link between Bone and Fat in Obese Children and Adolescents.International journal of molecular sciences · 2020Article
- TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy.Frontiers in immunology · 2020Review
- Mechanisms Involved in Childhood Obesity-Related Bone Fragility.Frontiers in endocrinology · 2019Review
- Updates on Osteoimmunology: What's New on the Cross-Talk Between Bone and Immune System.Frontiers in endocrinology · 2019Review
- Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma.Frontiers in immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have previously shown that through the production of high LIGHT levels, immune cells contribute to both osteoclastogenesis and bone destruction in Multiple Myeloma (MM)-related bone disease. With the aim of further exploring the mechanisms underlying the development of MM-related bone disease, here we focused on a possible role of LIGHT in MM patients with active bone disease despite the treatment received. We detected LIGHT over-expression by circulating CD14
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.